Involvement of kinesin family member 2C/mitotic centromere‐associated kinesin overexpression in mammary carcinogenesis

To elucidate the molecular mechanisms of mammary carcinogenesis and discover novel therapeutic targets for breast cancer, we previously carried out genome‐wide expression profile analysis of 81 breast cancer cases by means of cDNA microarray coupled with laser microbeam microdissection of cancer cells. Among the dozens of transactivated genes, in the present study we focused on the functional significance of kinesin family member 2C (KIF2C)/mitotic centromere‐associated kinesin (MCAK) in the growth of breast cancer cells. Northern blot and immunohistochemical analyses confirmed KIF2C/MCAK overexpression in breast cancer cells, and showed that it is expressed at undetectable levels in normal human tissues except the testis, suggesting KIF2C/MCAK to be a cancer–testis antigen. Western blot analysis using breast cancer cell lines revealed a significant increase in the endogenous KIF2C/MCAK protein level and its phosphorylation in G2/M phase. Treatment of breast cancer cells with small interfering RNA against KIF2C/MCAK effectively suppressed KIF2C/MCAK expression and inhibited the growth of the breast cancer cell lines T47D and HBC5. In addition, we found that KIF2C/MCAK expression was significantly suppressed by ectopic introduction of p53. These findings suggest that overexpression of KIF2C/MCAK might be involved in breast carcinogenesis and is a promising therapeutic target for breast cancers. (Cancer Sci 2008; 99: 62–70)

[1]  T. Mitchison,et al.  Identification and partial characterization of mitotic centromere- associated kinesin, a kinesin-related protein that associates with centromeres during mitosis , 1995, The Journal of cell biology.

[2]  R J Fletterick,et al.  The design plan of kinesin motors. , 1997, Annual review of cell and developmental biology.

[3]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[4]  Yusuke Nakamura,et al.  Cyclin K as a direct transcriptional target of the p53 tumor suppressor. , 2002, Neoplasia.

[5]  Yusuke Nakamura,et al.  Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. , 2003, Cancer research.

[6]  Yusuke Nakamura.  Isolation of p53‐target genes and their functional analysis , 2004, Cancer science.

[7]  Yusuke Nakamura,et al.  Oncogenic role of NALP7 in testicular seminomas , 2004, Cancer science.

[8]  Russell L. Malmberg,et al.  A standardized kinesin nomenclature , 2004, The Journal of cell biology.

[9]  J. Swedlow,et al.  Aurora B regulates MCAK at the mitotic centromere. , 2004, Developmental cell.

[10]  J. Shabanowitz,et al.  Aurora B Phosphorylates Centromeric MCAK and Regulates Its Localization and Microtubule Depolymerization Activity , 2004, Current Biology.

[11]  Yusuke Nakamura,et al.  Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. , 2004, International journal of oncology.

[12]  Yusuke Nakamura,et al.  Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas , 2004, Oncogene.

[13]  Yusuke Nakamura,et al.  Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas , 2005, Oncogene.

[14]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[15]  Yusuke Nakamura,et al.  Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. , 2005, Cancer research.

[16]  Pharmacological breast cancer therapy (review). , 2005, International journal of oncology.

[17]  Yusuke Nakamura,et al.  PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. , 2006, Cancer research.

[18]  Yusuke Nakamura,et al.  Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family , 2007, Breast Cancer Research.

[19]  Yusuke Nakamura,et al.  Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. , 2006, International journal of oncology.

[20]  Yusuke Nakamura,et al.  Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. , 2008, Cancer research.

[21]  MELK, maternal embryonic leucine zipper kinase, involved in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of Bcl-2 family , 2007 .

[22]  T. Katagiri,et al.  Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis , 2007, Oncogene.

[23]  Yusuke Nakamura,et al.  Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells , 2007, Cancer science.